行情

MCRB

MCRB

Seres
NASDAQ

实时行情|Nasdaq Last Sale

3.700
+0.270
+7.87%
已收盘, 16:00 03/30 EDT
开盘
3.440
昨收
3.430
最高
3.840
最低
3.440
成交量
32.78万
成交额
--
52周最高
7.39
52周最低
2.020
市值
2.63亿
市盈率(TTM)
-2.7742
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测MCRB价格均价为8.63,最高价位15.00,最低价为3.750。

EPS

MCRB 新闻

更多
  • Cowen主席:新冠疫情成为“已知的未知”,尽量让行动慢下来
  • 新浪财经 · 1小时前
  • 印尼央行行长:东南亚国家中央银行正在协调经济刺激行动
  • 新浪财经 · 1小时前
  • 高盛预期美国经济第二季度经济萎缩34%
  • 新浪财经 · 1小时前
  • 房多多2019年第四季度收入破10亿元 同比增长50%
  • 新浪财经 · 1小时前

所属板块

生物技术和医学研究
+4.00%
制药与医学研究
+4.75%

热门股票

代码
价格
涨跌幅

MCRB 简况

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.
展开

微牛提供Seres Therapeutics Inc(NASDAQ-MCRB)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的MCRB股票新闻,以帮助您做出投资决策。